There is one clinical trial.
The aim of the study is to associate dose of thromboprophylaxis with outcome in critically ill COVID-19 patients. This will be done by associating dose of thromboprophylaxis with 28-day mortality, survival outside ICU, thromboembolic event and bleeding complications.This was done in our earlier study for patients admitted in March and April (Clinicaltrials.gov NCT04412304 June 2 2020) but now we will include the patients admitted in May, June and half of July and we will ad the outcome of 90-day mortality.
Description: 28-day mortality from admission to ICU. Discontinue of ICU-care to palliative care counts as death.Measure: 28-day mortality Time: 28 days from ICU-admission
Description: Thromboembolic events are defined as pulmonary emboli (PE), deep venous thrombus (DVT) and ischemic stroke. PE is defined as PE verified by computer tomography or by findings of acute strain of the right heart on echocardiography combined with a clinical interpretation of the patients deteriorating as a probable PE stated in the medical records. DVT is defined as DVT verified with ultrasound. Ischemic stroke is defined as ischemic stroke verified by computer tomography.Measure: Incidence of thromboembolic events Time: 28 days from ICU-admission
Description: The event of bleeding will be defined by WHO modified bleeding scale as 1-4Measure: Incidence of bleeding events Time: 28 days from ICU-admission
Description: ICU-free days alive during 28 days from ICU-admission. Counts as 0 days if discharged to ward for palliative treatment.Measure: ICU-free days alive from ICU-admission Time: 28 days from ICU-admission
Description: 90-day mortality from admission to ICU.Measure: 90-day mortality Time: 90 days from ICU-admission
Description: Median value of Fibrin-D-dimerMeasure: Fibrin-D-dimer levels Time: 28 days from ICU-admission
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports